Modeling and Simulation - PK/PD Archives | Page 36 of 39

Publication

Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients

To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…

CertaraNovember 1, 2010

Publication

A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551

Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…

CertaraAugust 21, 2010

Publication

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

CertaraJuly 13, 2010

Publication

Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis

In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients…

CertaraJuly 1, 2010

Knowledge Base

What Does Clearance Mean?

Drug clearance is an extremely important topic in the science of pharmacokinetics. Drug clearance defines…

CertaraJune 13, 2010

Blog Knowledge Base

Understanding Volume of Distribution

CertaraJune 5, 2010

Publication

Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis

Phenylbutyric acid (PBA), which is approved for treatment of urea cycle disorders (UCDs) as sodium…

CertaraJune 1, 2010

Knowledge Base

What is Pharmacodynamics?

Starting with definitions is always helpful… so after defining pharmacokinetics, a definition for pharmacodynamics is…

CertaraMay 24, 2010

Knowledge Base

What is Pharmacokinetics?

You might think this is a simple question, especially for an expert in pharmacokinetics. Well,…

CertaraMay 16, 2010

Publication

Population Pharmacokinetic/Pharmacodynamic Model for a C.E.R.A. in Both ESA-naive and ESA-treated Chronic Kidney Disease Patients with Renal Anemia

This study aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model for C.E.R.A., a continuous erythropoietin…

CertaraMay 1, 2010

Modeling and Simulation – PK/PD

Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients

A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis

What Does Clearance Mean?

Understanding Volume of Distribution

Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis

What is Pharmacodynamics?

What is Pharmacokinetics?

Population Pharmacokinetic/Pharmacodynamic Model for a C.E.R.A. in Both ESA-naive and ESA-treated Chronic Kidney Disease Patients with Renal Anemia

Newsletter sign up

Quick links

Solutions

Contact